(Total Views: 601)
Posted On: 01/20/2021 12:27:54 AM
Post# of 155760
Calstang,
The lenzilumab trial started with ventilation as an exclusion criteria, so progression to ventilation or death is a very appropriate metric. Much more indicative than days to clinical improvement. Definitely a put up or shut up metric.
I believe they went to this endpoint, as the expanded patient population probably provides enough power to achieve statistical significance, even if the total percentage change between drug and placebo is not huge.
If lenzilumab meets their endpoint it will be great for patients and shareholders. As ohm20 notes, anything Lenzilumab can do Leronlimab can do better.
If proven, lenzilumab will be a good therapeutic, but a very distant second to leronlimab.
The lenzilumab trial started with ventilation as an exclusion criteria, so progression to ventilation or death is a very appropriate metric. Much more indicative than days to clinical improvement. Definitely a put up or shut up metric.
I believe they went to this endpoint, as the expanded patient population probably provides enough power to achieve statistical significance, even if the total percentage change between drug and placebo is not huge.
If lenzilumab meets their endpoint it will be great for patients and shareholders. As ohm20 notes, anything Lenzilumab can do Leronlimab can do better.
If proven, lenzilumab will be a good therapeutic, but a very distant second to leronlimab.
(3)
(0)
